US Bancorp
MAZE

US Bancorp’s Maze Therapeutics MAZE Stock Holding History

US Bancorp’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39K Buy
80
+71
+789% +$1.86K ﹤0.01% 3834
2026
Q1 		$269 Sell
9
-32
-78% -$1.41K ﹤0.01% 4072
2025
Q4 		$1.7K Buy
+41
New +$1.41K ﹤0.01% 3784

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

US Bancorp's MAZE Position: Q2 2026 in Review

US Bancorp increased its Maze Therapeutics (MAZE) stake by 789% in Q2 2026, buying an estimated $1.86K and bringing the position to 80 shares worth $2.39K. The position accounts for ﹤0.01% of the portfolio, ranked #3834.

US Bancorp first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • US Bancorp held 80 shares of Maze Therapeutics worth $2.39K as of Q2 2026.
  • US Bancorp bought 71 Maze Therapeutics shares in Q2 2026, an estimated $1.86K.
  • Maze Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3834 holding.
  • US Bancorp first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.